[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":277},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,84,106,130,160,184,208,236,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280",false,"NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[26,27,28,29,30],"Helicobacter Pylori Infection","Dyspepsia","Peptic Ulcer Disease","Helicobacter Pylori","H Pylori",[32,33,34,35,36,37,27],"Helicobacter pylori","Helicobacter pylori eradication","Vonoprazan","Esomeprazole","Levofloxacin","Triple therapy","RECRUITING","2026-04-18",{"date":41,"type":42},"2026-04-22","ACTUAL",{"date":44,"type":20},"2026-04-15",{"date":46,"type":20},"2026-08-14",{"name":48,"class":49},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","OTHER",2,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":17,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100631927","education-based-oral-health-promotion-intervention-during-pregnancy-implementation-protocol-in-bangladesh-100631927","NCT07507045","Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh","Oral Health Promotion Intervention During Pregnancy: Bangladesh Perspective","E-OHP","Inclusion Criteria:\n\n* Pregnant women attending ANC services at participating UHCs\n* Gestational age ≤24 weeks at enrolment to allow follow-up\n* Age 18 years or older\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of severe medical or obstetric complications requiring immediate referral\n* Current participation in another behavioural or oral health intervention study\n* Conditions preventing participation in oral examination procedures",true,"FEMALE",{"count":62,"type":20},688,[64],"NA","In Bangladesh, over 95% of pregnant women suffer from gum disease (gingivitis or periodontitis), yet oral health is rarely included in standard pregnancy check-ups. This study tests a new \"Integrated Oral Health Promotion Package\" to see if teaching oral hygiene during routine prenatal visits can improve the health of mothers. Pregnant women (ages 18-45) will be divided into two groups. The intervention group will receive two face-to-face education sessions with a dental assistant, learn a specific tooth-brushing technique, and receive weekly SMS text reminders to brush their teeth. The control group will receive the standard pregnancy care currently offered in Bangladesh. Researchers will track the participants for 12 weeks to see if the education and reminders lead to better brushing habits (twice-daily) and cleaner teeth and gums compared to the standard care group.",[67,68,69],"Pregnancy","Periodontal Diseases","Oral Hygiene, Oral Health",[71,67,72,73],"Maternal oral health","Antenatal care","Cluster randomized trial","NOT_YET_RECRUITING","2026-03-29",{"date":77,"type":42},"2026-04-02",{"date":79,"type":20},"2026-05-01",{"date":81,"type":20},"2026-11-01",{"name":48,"class":49},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":83},"100629138","frequency-of-mafld-and-its-association-with-nutritional-status-and-metabolic-risk-factors-in-a-rural-population-of-bangladesh-100629138","NCT07470749","Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh","Inclusion Criteria:\n\n* Age 18 years or above\n* Resident of the selected community\n\nExclusion Criteria:\n\n* Pregnant women\n* Severe illness precluding participation like paralysis, bed ridden, cancer etc",{"count":91,"type":20},1000,"OBSERVATIONAL","Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly recognized cause of chronic liver disease and is closely linked with obesity, metabolic abnormalities, and nutritional status. Data on the frequency of MAFLD and its associated metabolic and nutritional factors in rural populations of Bangladesh are not up to date.\n\nThis study aims to determine the frequency of MAFLD and to evaluate its association with nutritional status and metabolic risk factors among adults in a rural population of Bangladesh. Eligible participants will undergo clinical assessment, anthropometric measurements, laboratory evaluation of metabolic parameters, and abdominal ultrasonography for the detection of hepatic steatosis. Nutritional status will be assessed using standard anthropometric and clinical criteria.\n\nThe findings of this study are expected to provide baseline epidemiological data on MAFLD in rural Bangladesh and to help identify associated metabolic and nutritional risk factors.",[95,96,97],"MAFLD","Metabolic Abnormalities","Obesity & Overweight","2026-03-10",{"date":100,"type":42},"2026-03-13",{"date":102,"type":42},"2025-12-04",{"date":104,"type":20},"2026-10-31",{"name":48,"class":49},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":83},"100607226","clinical-outcome-of-intra-articular-injection-of-autologous-platelet-rich-plasma-in-anterior-cruciate-ligament-injury-100607226","NCT07185802","Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.","ACL","Inclusion criteria:\n\n* Patients of both sexes who are older than 18 years and younger than 50 years\n* 3 or Less than 3-months history of knee injuries\n* ACL injury MRI Grade 1 (Low) and medium Grade 2 (Medium) grade\n* ACL injury associated with Grade 1 or 2 Posterior cruciate ligament (PCL) tear and\u002For Grade 1 or 2 meniscal tear\n* The Complete Blood Count (CBC) report shows a hemoglobin \\> 10gm\u002Fdl and platelet count \\>150,000\u002Fmicroliter prior to the procedure\n* Capable of comprehending informed consent\n\nExclusion criteria:\n\n* Patients who have had intra articular corticosteroid injections in the index knee during the last 12 weeks\n* Patients who are taking systemic steroid\n* Patients who are younger than 18 and older than 50 years\n* Those with a history of platelet disorders or on the therapeutic anticoagulant or anti platelet drugs\n* Hemoglobin below 10 gm\u002Fdl\n* Platelet count \\\u003C150000\u002Fmicroliter\n* Complete tear of both bundles on MRI\n* Grade 3 or more PCL and meniscal tear on MRI\n* Previous or concurrent ligament reconstruction in the index knee joint.\n* Connective tissue disorders like Marfan Syndrome, Ehler-Danlos Syndrome etc.\n* Any inflammatory disease like Rheumatoid Arthritis, spondyloarthritis, gout, pseudogout etc involving the knee joint.","50 Years",{"count":115,"type":20},52,[64],"This clinical trial will evaluate the effectiveness of platelet-rich plasma (PRP) injections for patients with anterior cruciate ligament (ACL) injury. ACL injuries commonly cause knee instability, pain, and reduced function, and rehabilitation alone may not fully restore recovery in all patients. PRP is prepared from a small sample of the patient's own blood and contains natural growth factors that may promote healing and improve joint function.\n\nIn this study, participants will be randomly assigned to one of two groups. The experimental group will receive a single ultrasound-guided injection of PRP into the knee joint along with a standard rehabilitation program. The control group will receive the rehabilitation program alone.\n\nParticipants will be followed up at 3 weeks, 8 weeks, and 16 weeks after treatment. At each follow-up visit, knee function, pain level, and physical performance will be assessed using validated outcome measures. The primary aim is to determine whether PRP provides additional benefit compared with rehabilitation alone in improving function and reducing symptoms in ACL-injured patients.\n\nThis study will provide new evidence about the role of PRP in ACL management, which may help guide future treatment decisions.",[119],"Anterior Cruciate Ligament",[121],"PRP in ACL injury","2025-09-19",{"date":124,"type":42},"2025-09-22",{"date":126,"type":42},"2025-08-27",{"date":128,"type":20},"2026-08-26",{"name":48,"class":49},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":83},"100605347","phase-2-role-of-methotrexate-in-ultrasound-proven-synovitis-in-primary-knee-oa-100605347","NCT07161336","Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","Role of Methotrexate in Ultrasound Proven Synovitis in Patients With Knee Osteoarthritis : A Randomized Controlled Trial","MTX in knee OA","Inclusion Criteria:\n\n* Men and women aged between 40 to 70 years\n* Patients fulfilling American College of Rheumatology (ACR) clinical and radiological criteria for knee OA. (knee pain + at least 3 of 5 that not including \"no palpable warmth\")\n* Knee pain on most days for at least 6 months, with a pain VAS of at least 40mm\n* Radiological grading of OA with Kallgren-Lawrence grade of 2 to 3\n* Patients with the presence of knee synovitis in Musculoskeletal ultrasound\n\nExclusion Criteria:\n\n* Any known inflammatory arthritis\n* BMI \\>= 40 kg\u002Fm2\n* Abnormal renal (e.g. abnormal renal function Creatinine clearance \\\u003C35 ml) hepatic (including active hepatitis B, hepatitis C, abnormal liver function), hematological (e.g. white cell count \\\u003C 4 × 109\u002FL, platelets \\\u003C100 ×109\u002FL, or hemoglobin \\\u003C 9 g\u002FdL), function\n* Use of intra-articular, intramuscular or oral corticosteroids in previous 4 weeks\n* History knee joint surgery, Charcot joint\n* Severe valgus knee deformity (angle of genu valgum \\> 30°)\n* Use of any disease modifying agents (e.g. hydroxychloroquine or sulfasalazine) in previous 3 months\n* Allergic to MTX\n* Pregnant or lactating women","40 Years","70 Years",{"count":141,"type":20},70,[143],"PHASE2","Background:\n\nOsteoarthritis (OA) is a leading cause of disability worldwide, with limited treatment options and many patients suffering from chronic pain. Modern imaging has revealed that OA involves complex changes in cartilage, subchondral bone, and synovium. Pain in OA is often linked to synovitis, which is common in the condition. Methotrexate (MTX), a proven treatment for synovitis in inflammatory arthritis like rheumatoid arthritis and has a well-known safety profile. The proposal suggests that using MTX may have potential to treat symptomatic knee OA with USG (musculoskeletal ultrasound) proven synovitis by reducing synovitis and as a result, alleviate pain.\n\nObjectives:\n\nTo assess the role of methotrexate in primary knee osteoarthritis associated with ultrasound proven synovitis.\n\nMethods:\n\nThis randomized Controlled trial will be conducted in the department of Rheumatology, Bangladesh Medical University (BMU) from July 2025 to June 2026. A total of 70 patients will be enrolled with primary knee OA diagnosed on the basis of ACR Criteria for Knee OA with informed written consent. MSK USG examinations of knee joint and scoring (OMERACT SCORE) will be performed to detect synovitis by a rheumatologist expert in MSK US. Then randomization will be done into group A and group B following a randomization table, each consisting of 35 patients. Consecutive sampling techniques will be followed. One group will receive MTX (start with 15 mg per week for the first 2 weeks then increase to 20 mg and continue for the remaining period if tolerated) and Both groups of patients will be allowed to take NSAIDs on a requirement basis with documentation and follow non-pharmacological treatment of OA. At the end of 3rd and 6th month pain and functional status will be assessed by WOMAC, VAS and quality of life will be assessed by using Bangla version of SF-12. At the end of 6th month improvement of synovitis will be seen by MSK USG of involved knees with OMERACT scoring. Primary endpoint for efficacy will be assessed at the end of 24th week by WOMAC. Secondary endpoints will be determined by VAS and SF-12. Adverse effects will be assessed by history, physical examinations and investigations. The data will be analyzed by using the latest version SPSS software (Version 29). Results will be recorded using means and standard deviations. Results will be compared among two groups with a 95% confidence interval and a p- value of \\\u003C 0.05 will be considered statistically significant. The degrees of statistical significance between groups will be analyzed by unpaired t test (for quantitative normally distributed data) and Mann Whitney U test if there is skewed distribution. Qualitative data in between groups will be analyzed by the chi square test. Probabilities of associations will be assessed by calculating Pearson's rank correlation coefficient. P-value \\\u003C0.05 will be regarded as statistically significant. The nature, purpose and implication of the study as well as the entire spectrum of benefits and risks of study will be explained to the patients. Privacy and confidentiality of the subject will be maintained. Each patient will enjoy the right to participate and or withdraw from the study at any point of the study period. Ethical clearance will be obtained from the institutional Review Board (IRB) of BMU.",[146,147,148],"Osteo Arthritis of the Knee","Synovitis of Knee","Methotrexate",[150,151,148],"knee OA","synovitis","2025-09-07",{"date":154,"type":42},"2025-09-12",{"date":156,"type":42},"2025-07-30",{"date":158,"type":20},"2026-08-30",{"name":48,"class":49},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":60,"minAge":17,"maxAge":139,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":83},"100599659","enhanced-recovery-after-surgeryeras-following-gynaecological-oncology-surgery-in-a-tertiary-level-hospital-100599659","NCT07087366","Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital","Enhanced Recovery After Surgery(ERAS) Pathway Following Gynecological Oncology Surgery in a Tertiary Level Hospital:A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients between the age of 18-70 years,\n* diagnosed case with cervical, uterine or ovarian cancer,\n* Admitted for surgical management .\n\nExclusion Criteria:\n\n* Patients with severe comorbidity, including DM,CRD,CLD\n* patients with American Society of Anesthesiologists risk ≥ 4,\n* severe organ dysfunction or failure.",{"count":168,"type":20},130,[64],"Enhanced recovery after surgery (ERAS) protocols are multimodal perioperative care pathways designed to achieve early recovery after surgical procedures by maintaining preoperative organ function and reducing the profound stress response following surgery.\n\nThe principle of ERAS is to optimize the patient's health before surgery, minimize stress to the body, and restore function to normal rapidly by taking steps before, during, and after surgery, to decrease the length of stay in the hospital, reduce recovery time, prevent complications, readmissions, same day discharge (SDD) and patient's satisfaction.\n\nThe aim of this study is to introduce the ERAS recommendations into the management of gynaecological surgical procedures in compared to conventional procedures.\n\nAfter taking permission from Institutional Review Board (IRB) of BSMMU, the proposed study will be started. After taking informed written consent and matching eligibility criteria, a total 160 patients will be selected in this prospective randomized control study. This study will be conducted in the Department of gynecological oncology, BSMMU for two years from April 2024 to March 2026. There will be two group in this study, patients of Group A will be selected for ERAS protocol from preoperative to postoperative event up to follow up. Patients of Group B will be selected for conventional method. Outcome of both procedure in terms of hospital stay, costs, requirement of analgesia and complications will be compared. Statistical analyses of the results will be obtained by using window-based computer software devised with Statistical Packages for Social Sciences (SPSS-25).",[172,173],"ERAS","Cancer",[175],"RCT","2025-08-02",{"date":178,"type":42},"2025-08-07",{"date":180,"type":42},"2025-06-01",{"date":182,"type":20},"2027-06-30",{"name":48,"class":49},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":83},"100588040","phase-3-safety-and-efficacy-of-baricitinib-on-skin-tightening-in-diffuse-cutaneous-systemic-sclerosis-a-comparative-study-with-methotrexate-100588040","NCT06936215","Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate","BardSSc","Inclusion Criteria:\n\n* 1\\. Diagnosis of diffuse cutaneous systemic sclerosis, as classified using the 2013 American College of Rheumatology\n\n  2\\. Diffuse cutaneous systemic sclerosis as defined by 2001 LeRoy and Medsger 3. Disease duration ≤ 60 months (defined as time from the first non-Raynaud phenomenon manifestation) 4. mRSS score ≥ 10 at baseline\n\nExclusion Criteria:\n\nSubjects with any of the following characteristics\u002Fconditions will not be included in the study:\n\n1. Rheumatic disease other than systemic sclerosis. it is acceptable to include patients with fibromyalgia and scleroderma-associated myopathy\n2. Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit\n3. Major surgery (including joint surgery) within 8 weeks prior to screening visit\n4. Any infected ulcer prior to treatment\n5. Subjects with any serious bacterial infection (e.g.,chronic pyelonephritis, osteomyelitis, or bronchiectasis) .\n6. Oral corticosteroids \\>10 mg\u002Fday of prednisone or equivalent.\n7. Mycophenolate mofetil \\> 2 grams\u002Fday prior to baseline\n8. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin) ≤ 40% of predicted\n9. Current clinical, radiographic, or laboratory evidence of active TB.\n10. Positive for hepatitis B surface antigen at or within 30 days of screening.\n11. Positive for hepatitis C antigen at or within 30 days of screening.\n12. Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.\n13. Pregnant or breastfeeding female subjects and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug.\n14. History of any malignancy in the last 5 years\n15. History of SSc Renal Crisis within the 6 months prior to baseline.\n16. Patients with a history of anaphylaxis to Baricitinib or methotrexate\n17. Any of the following lab results at screening:\n\n    * Hemoglobin \\\u003C8 g\u002Fdl\n    * White Blood Cell count \\\u003C3.0 x 109\u002FL;\n    * Absolute Neutrophil count \\\u003C1.2 x 109\u002FL;\n    * Platelet count \\\u003C100 x 109\u002FL;\n    * Absolute Lymphocyte count \\\u003C0.75 x 109\u002FL.\n    * ALT \\> 3 × the upper limit of normal (ULN) of normal at screening\n    * Estimated glomerular filtration rate \\[GFR\\] \\\u003C60mL\u002Fmin\u002F1.73 m2",{"count":192,"type":20},24,[194],"PHASE3","Systemic sclerosis (SSc) is a systemic autoimmune disease. It causes progressive skin tightening, pulmonary fibrosis, organ damage and many other physical dysfunctions. It is divided into two types, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSCc). Skin involvement in systemic sclerosis is assessed by modified Rodnan skin score (mRSS). Methotrexate is a drug used in the treatment of skin tightening in SSc but has inconsistent response . Janus kinase (JAK) inhibitors are a class of drugs that may be used in skin involvement in dcSSc. Among them, baricitinib, a JAK 1\u002F2 inhibitor, has shown some efficacy in dcSSc. The aim of this study is to assess the efficacy and safety of baricitinib on skin tightening in dcSSc patients. This open label randomized clinical trial will be conducted in department of rheumatology, BSMMU. Systemic sclerosis will be diagnosed by ACR\u002FEULAR classification criteria 2013. Among them who have diffuse cutaneous involvement will be considered primary entry criteria for this study. Consecutive sampling method will be applied. Participants will be divided into two groups, group A and group B. Group A will be put on tab. baricitinib 4 mg daily and group B will be put on tab. methotrexate 25 mg weekly with folic acid 5 mg weekly. All participants will be assessed for mRSS, CDAI at baseline and laboratory tests like CBC, ESR, CRP, SGPT, serum creatinine, CXR P\u002FA view etc. Follow up will be done at 4, 12, 24 weeks. Response to treatment will be assessed by modified Rodnan skin score. Primary endpoint of efficacy will be assessed by the end of 24th week. adverse effects will be assessed by history, physical examination and investigations. The data will be analyzed by SPSS version 25. results will be recorded using means and standard deviations. Result will be compared among groups with a 95% confidence interval and a p-value 0f\\\u003C0.05. The degrees of statistical significance between groups will be analyzed by unpaired t test (for quantitative normally distributed data) and Mann Whitney U test for skewed distribution. Qualitative data in between groups will be analyzed by chi square test. Probabilities of association will be assessed by Spearman's rank correlation coefficient. P value of \\\u003C 0.05 will be regarded as statistically significant.",[197],"Diffuse Cutaneous Systemic Sclerosis",[199],"Baricitinib in diffuse cutaneous systemic sclerosis","2025-04-12",{"date":202,"type":42},"2025-04-20",{"date":204,"type":42},"2024-01-01",{"date":206,"type":20},"2025-05",{"name":48,"class":49},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":60,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":83},"100585024","phase-2-semaglutide-in-women-with-polycystic-ovary-syndrome-and-obesity-100585024","NCT06896981","Semaglutide in Women With Polycystic Ovary Syndrome and Obesity","Comparison Between the Effects of Low-Dose Semaglutide With Metformin vs. Metformin Alone Over Metabolic Profile in Obese Polycystic Ovary Syndrome: A Phase II Randomized Controlled Trial","Inclusion Criteria:\n\nReproductive-aged women with PCOS diagnosed according to International evidence based guidelines 2023 and obesity\n\nExclusion Criteria:\n\n1. Having DM, other significant systemic diseases- chronic kidney disease (eGFR \\\u003C60mL\u002Fminute\u002F 1.73 m2 BSA), chronic liver disease (ALT \\>3 × ULN), and heart failure\n2. Patients having PCOS mimicking endocrine disorders (untreated thyroid dysfunctions, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, acromegaly, hypothalamic disorder etc.)\n3. Those taking any other weight loss medications (eg., orlistat, liraglutide) within the last 3 months\n4. Those who have undergone bariatric surgery\n5. Any conditions causing weight loss (thyrotoxicosis, Addison's disease, chronic infection, connective tissue disorder, cancer, etc)\n6. Secondary causes of obesity (major mood disorders, steroids, valproate, oral contraceptives, etc)\n7. Contraindications for semaglutide: personal or family history of medullary carcinoma of the thyroid, history of acute pancreatitis, gallbladder disease\n8. Planning for pregnancy or current pregnancy\u002F lactation","10 Years","45 Years",{"count":218,"type":20},30,[143,194],"Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations helps in the control of symptoms, including subfertility. Metformin has been commonly used to decrease insulin resistance and weight in PCOS patients suffering from obesity. Glucagon-like peptide (GLP-1) agonist semaglutide is also effective in managing different metabolic features, including obesity and insulin resistance. There is limited data about using a combination of semaglutide and metformin in women with PCOS suffering from obesity. This study aims to compare the metabolic changes after giving a combination of low-dose semaglutide and metformin vs. metformin alone over 12 weeks among women with PCOS and obesity. This open label randomized trial will be conducted in the Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University (BSMMU). After obtaining informed written consent, a total of 30 patients with PCOS and obesity will be enrolled conveniently (sampling) in the study as per inclusion and exclusion criteria from the outdoor, indoor, and PCOS clinic, Endocrinology, BSMMU. Study participants will be divided into two groups randomly by a computerized random number generator (allocation). One study arm will be treated with low-dose subcutaneous semaglutide (0.25 mg\u002Fweek for 4 weeks followed by 0.5mg per week for 12 weeks) in combination with metformin (500 mg bid). Another study arm will receive monotherapy with metformin (500 mg bid) for treatment. Both arms will receive standard unified lifestyle advices. Patients will be followed every four weeks for clinical data for up to twelve weeks. Laboratory tests will be done at baseline and the final follow-up in an 8 - 12 hours of fasting state. Two mL of blood will be used to measure glucose using the glucose oxidase method on the same day of sample collection. The remaining three mL of blood will be centrifuged, the serum will be separated and analyzed for insulin, TT, SHBG, ALT and lipid profiles on the same day. All the clinical and biochemical information will be documented in a pretested, semi-structured case record form. Recorded data will be entered, edited, and analyzed by SPSS software version 25.0. Data will be expressed as frequencies \\& percentages (%) for qualitative values and mean \\& standard deviation (±SD) or median \\& inter-quartile range (IQR) for quantitative values depending on their distribution. Kaplan Meier Curve will be used to show the comparison between primary outcomes. For quantitative variables, a comparison between two groups will be done using Mann-Whitney U test, and within a group, a paired t-test or Wilcoxon test will be used. For qualitative variables, a comparison between two groups will be tested using Pearson's chi-square test and within the group by the McNemar test. Regression Analysis will be done to correlate between treatment and outcome. Any p-value below 0.05 will be considered statistically significant. Confidentiality will be strictly maintained. Informed written consent will be taken from patients.",[222,223],"Polycystic Ovary Syndrome (PCOS) Women","Obesity",[225,223,226,227],"Polycystic ovary syndrome","Semaglutide","Metformin","2025-03-27",{"date":230,"type":42},"2025-04-02",{"date":232,"type":42},"2025-02-01",{"date":234,"type":20},"2025-12-31",{"name":48,"class":49},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":83},"100565449","human-papillomavirus-association-and-genomic-exploration-in-head-neck-squamous-cell-carcinomas-100565449","NCT06642324","Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas","Exploration of Human Papillomavirus Association and Genomic Characteristics in Head and Neck Squamous Cell Carcinomas in Bangladesh","HPV & HNSCC","Inclusion Criteria:\n\n1. Patient Age: adult (\\> 18 years)\n2. Head and neck squamous cell carcinoma diagnosed by biopsy (Histopathology confirmed HNSCC).\n3. Diagnosed cases specific Head-Neck sub-sites: (oral cavity, oropharynx, hypopharynx, larynx, tongue)\n4. Patient's Consent\n\nExclusion Criteria:\n\n1. Patient Age: children (\\\u003C 18 years)\n2. Cancers of any part of the body other than the head-neck region.\n3. People without HNSCC\n4. Any chronic diseases, genetic diseases, acute\u002Fchronic infectious diseases, etc. -",{"count":245,"type":20},550,"Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in Bangladesh with a high incidence and mortality rate. While traditional risk factors like tobacco and betel nut chewing contribute to HNSCC incidence, the emergence of HPV-associated HNSCC presents a unique challenge. The main goal of this observational study is to explore the prevalence, risk factors, and biological mechanisms underlying food habits and HPV-driven HNSCC in the population and identify the genomic changes and characteristics related to this malignancy. This study will provide the prevalence of HPV-associated HNSCC and screening the HPV typing in the Bangladeshi population, identify risk factors, and any biologically driven mechanisms causing HNSCC.",[248,249],"Head Neck Cancer","Oropharyngeal Neoplasms","2024-12-28",{"date":252,"type":42},"2024-12-31",{"date":254,"type":42},"2024-04-30",{"date":256,"type":20},"2025-09-30",{"name":48,"class":49},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":83},"100559964","comparative-analysis-of-cost-effectiveness-between-sulfonylureas-and-dpp4-inhibitors-in-combination-with-metformin-in-treatment-of-type-2-diabetic-patients--a-retrospective-observational-study-100559964","NCT06570980","Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","Inclusion Criteria:\n\n* New onset type2 diabetes mellitus diagnosed for 2 -5 years.\n* Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Age 18 years or above.\n* Both male and female.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Unwillingness to participate or unwillingness to give written informed consent.\n* Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.\n* Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.\n* Diabetes related complications at the time of diagnosis.",{"count":265,"type":20},200,"The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.",[268],"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","2024-08-22",{"date":271,"type":42},"2024-08-26",{"date":273,"type":42},"2023-08-25",{"date":275,"type":20},"2024-08-30",{"name":48,"class":49},""]